Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Phase 2TerminatedNCT00127595

Gustave Roussy, Cancer Campus, Grand Paris28 enrolled

Overview

This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Carcinoma, Transitional Cell

Interventions

gemcitabine, oxaliplatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Transitional cell carcinoma * Histologically-proven * Locally advanced unresectable or metastatic * With at least one measurable target * Informed consent signed Exclusion Criteria: * Previous chemotherapy * Previous radiotherapy * Performance status \>=2 * Peripheral neuropathy \>=1

Locations (1)

Institut Gustave Roussy

Villejuif, France

Outcomes

Primary Outcomes

response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)

Secondary Outcomes

overall survival

disease free survival

toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.